The purpose of this study is to compare the use of oral apixaban to subcutaneous enoxaparin for venous thromboembolism (VTE) prophylaxis in postpartum women at high risk for VTE. The primary goal is to evaluate medication adherence rates and patient satisfaction with the treatment.
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
General Treatment Convenience Assessed by a Study-Specific Patient Satisfaction Questionnaire
Timeframe: up to 6 weeks postpartum
Medication Adherence Rate Assessed by Patient Self-Report
Timeframe: Up to 6 weeks postpartum
Treatment-Related Pain Intensity Assessed by a Visual Analog Scale (VAS)
Timeframe: Up to 6 weeks postpartum
Patient Treatment Preference and Recommendation Assessed by Self-Report
Timeframe: Up to 6 weeks postpartum